CML Highlights of ASH 2023

Clinical Highlights

Expert

Dr Naranie Shanmunagathan
Royal Adelaide Hospital and SA Pathology,
Adelaide (Australia)

00:00 Welcome and introduction
02:46 Abstract 865: Australian ASCEND study:
Excellent early and molecular responses observed with Asciminib treatment for CP-CML: Results from the ALLG CML13 ASCEMBL Study (Yeung D et al)
12:04 Abstract 446: Update from the German TIGER trial:
Treatment-free remission after Nilotinib plus Peg-Interferon α induction and Peg-Interferon α maintenance therapy for newly diagnosed CML patients (Hochhaus A et al)

Biological Highlights

Expert

Professor Michael Deininger
Versiti Blood Research Institute
Milwaukee (USA)

00:00 Introduction
01:28 Abstract 1785: Loss of function of SETD2 tumor suppressor in chronic myeloid leukemia (CML) progenitors fosters genomic instability and enhances chronogenic potential (De Santi S et al.)
02:35 Abstract 3151: Multiomic single-cell analysis identifies Van Willebrand factor and TIM3 expressing BCR-ABL1 chronic myeloid leukemia stem cells (Nilsson MS et al.)
04:24 Abstract 449: Impact of mutations in blood cancer-related genes on clinical outcomes in chronic myeloid leukemia in chronic phase (CML-CP) after ≥ tyrosine kinase inhibitors (TKIs) in the Ascembl trial (Branford S et al.)
12:03 Abstract 862: Nutrient-sensitising drug repurposing screen identifies Lomerizine as a mitochondrial metabolism inibitor in chronic myeloid leukemia (Khalaf A et al.)
19:48 Questions and Answers
25:17 Thanks and Conclusion